Over the years, Ellex has evolved from a small scientific laser company to a global leader in ophthalmic laser technology. Our steady expansion includes local sales and service support offices in North America, Japan, Europe and Australia and a network of distribution partners in more than 100 countries.
6 June 2017
Highlight: Chinese government confirms regulatory approval for iTrack™ until 23 May 2022 – the only MIGS device to treat glaucoma approved in this market Adelaide, Australia, 6 June 2017– Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced an extension of regulatory approval in China for its minimally invasive glaucoma surgery (MIGS) device, Ellex iTrack™. On 2 June 2017, Ellex received advice from the Chinese government that the Ellex iTrack™ device’s approval for sale in China has been extended until 23 May 2022. Ellex iTrack™ is the only MIGS device approved for sale in China. China is a key market segment for Ellex iTrack™ and the Company is working with its distributor to train doctors in the iTrack™ surgery technique and build sales in the country. ABOUT ELLEX Ellex designs, develops, manufactures and sells innovative products that help eye surgeons around the world to effectively and efficient
Acquisition of iTrack™ royalty commitment removes all royalty payments on future sales, with 100% of all future iTrack™ revenue now attributed to Ellex
30 May 2017
Adelaide, Australia, 30 May 2017 Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that it has acquired the future iTrack™ royalty commitment from ISCI Holdings Inc., the original vendor of the iTrack™ business. Ellex has agreed to purchase all future royalties for its proprietary iTrack™ device at a total cost of US$2.15 million. This includes an initial payment of US$0.650 million made on 25 May 2016. The final instalment of US$1.5m will be made on 15 September 2017. The Company believes that the acquisition price represents good value at a time when it prepares to accelerate global sales and marketing efforts for the iTrack™ product. The original asset purchase agreement between Ellex and ISCI Holdings Inc. (formerly iScience International Inc.) stipulated that royalty payments for the period of five years through to 31 December 2018 were to be equal to 12% of the first US$4,100,000 of Net Reven
5 May 2017
Adelaide, Australia, 5 May 2017 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that its proprietary iTrack™ minimally invasive glaucoma surgery (MIGS) technology will figure in the official scientific program of the annual American Society of Cataract and Refractive Surgery (ASCRS), Los Angeles, 5-9 May 2017. This will also coincide with the release of positive, interim 24-month ABiC™ case series data by Dr. Mark J. Gallardo (El Paso Eye Surgeons, Texas, USA). ASCRS 2017 The annual ASCRS meeting is the preeminent scientific and industry event for cataract and refractive surgeons and medical personnel in the ophthalmic industry. Key physician presentations and courses featuring Ellex iTrack™ and ABiC™ at ASCRS 2017 are listed below. 1. ASCRS MIGS Skills Transfer Wetlab Session Monday, 8 May 2017 ABiC™ with iTrack™ will figure alongside other leading MIGS procedures, such as iStent (Glaukos Corp
Annual Report 2016
View Share Price
Note: Prices are delayed by at least 20 minutes and are sourced from the Australian Stock Exchange. Retrieving price information indicates your acceptance of the conditions.